Previous close | 1.4050 |
Open | 1.4792 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 1.4020 - 1.5100 |
52-week range | 1.4020 - 11.2400 |
Volume | |
Avg. volume | 499 |
Market cap | 633,781 |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.
Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.
Key Financial Metrics Highlighted Amidst Clinical Advancements